Today's Daily Dose brings you news about Clementia's Palovarotene NDA submission; Dermira's near-term catalyst; promising results of Pfizer and Eli Lilly's phase III study of investigational Tanezumab in patients with osteoarthritis pain, and better-than-expected Q3 financial results of USANA Health.
from RTT - Biotech https://ift.tt/2PhkFBm
via IFTTT
No comments:
Post a Comment